Overview

Comparative Study of Different Neoadjuvant Therapies Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer

Status:
Completed

Trial end date:
2015-07-01

Target enrollment:
0

Participant gender:
Female

Summary

For stage Ib2-IIa2 cervical cancer patients, neoadjuvant therapy followed by radical hysterectomy and pelvic lymphadenectomy is one of the managements. Post-operative concurrent chemo-radiotherapy is necessary if the patients have high-risk factors, including positive surgical margin, parametrium and pelvic nodes. Our previous retrospective study showed that combination of neoadjuvant chemotherapy and brachytherapy reduced the proportion of post-operative concurrent chemo-radiotherapy compared to neoadjuvant chemotherapy alone.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Chinese Academy of Medical Sciences

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel

Criteria

Inclusion Criteria:

- Histology confirmed cervical cancer

- Clinical stage Ib2 or IIa2 (FIGO 2009)

Exclusion Criteria:

- Patients who not suitable for surgery

- Personal history of pelvic radiotherapy